WHO grants Emergency Use Listing to Biological E Corbevax vaccine
Hyderabad: Biological E. Limited, a Hyderabad-based Vaccines and Pharmaceutical company, has announced that the World Health Organisation (WHO) has granted an Emergency Use Listing (EUL) to their CORBEVAX vaccine, which is India's first indigenously developed COVID-19 vaccine that is based on protein sub-unit platform.
The Drugs Controller General of India (DCGI) already approved CORBEVAX for restricted use in emergency among adults, adolescents and young children in a sequential manner from December’21 to April’22; as well as India’s first heterologous COVID-19 booster shot for adults age 18 and above in June’22. BE supplied 100 Million Doses of CORBEVAX to the Government of India which were then utilized in pan-India immunization campaigns; mainly in 12-14 yr old children.
Ms. Mahima Datla, Managing Director, Biological E. Limited, said, ``We are pleased with the WHO EUL because it would help us to use the platform to continue developing COVID-19 vaccines as and when it starts impacting public health. We are confident that this endorsement from WHO will bolster our global fight against COVID-19.’’
She further added, “We understand that several countries come under a lot of fiscal pressure when it comes to dealing with COVID-19. We aim to reach the people in those countries with CORBEVAX , just as we have done with all our other vaccines. Our committment is to provide affordable and accessible vaccines that are of high quality and the WHO EUL lays a path for us to make that possible.”
Ms. Mahima further added, “While several companies which entered the field of vaccine development & manufacturing during the COVID-19 pandemic exited soon afterwards either due to paucity of funds or lack of success, BE continues to remain committed to develop and provide access to high quality affordable vaccines globally by constantly enlarging its portfolio of offerings.’’
Read also: Biological E Corbevax safe, immunogenic in 5-18 age group
